anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a high-efficient sterilization shampoo, belonging to the field of sanitary article, and relating to special shampoo. The invention aims at providing a high-efficient and safe sterilization shampoo product which is processed by adopting modern biotechnology product. The formulation of the invention mainly includes: surface active agent, lather booster, tackifier, conditioner, pigment and essence. The main technical characteristic of the invention is to add a low-cost, high-efficient, safe and natural disinfectant through modern biotechnology process. The disinfectant processed through modern biotechnology from natural starting crude has an antisepticize function, with safe and high-efficient characteristics. The shampoo is needless to add preservative.
Approximately 30-60% of people suffer from olfactory dysfunction (OD) such as hyposmia or anosmia after being diagnosed with COVID-19; 15-20% of these cases last beyond resolution of the acute phase. Previous studies have shown that olfactory training can be beneficial for patients affected by OD caused by viral infections of the upper respiratory tract. The aim of the study is to evaluate whether a multisensory olfactory training involving simultaneously tasting and seeing congruent stimuli is more effective than the classical olfactory training. We recruited 68 participants with persistent OD for two months or more after COVID-19 infection; they were divided into three groups. One group received olfactory training which involved smelling four odorants (strawberry, cheese, coffee, lemon; classical olfactory training). The other group received the same olfactory stimuli but presented retronasally (i.e., as droplets on their tongue); while simultaneous and congruent gustatory (i.e., sweet, salty, bitter, sour) and visual (corresponding images) stimuli were presented (multisensory olfactory training). The third group received odorless propylene glycol in four bottles (control group). Training was carried out twice daily for 12 weeks. We assessed olfactory function and olfactory specific quality of life before and after the intervention. Both intervention groups showed a similar significant improvement of olfactory function, although there was no difference in the assessment of quality of life. Both multisensory and classical training can be beneficial for OD following a viral infection; however, only the classical olfactory training paradigm leads to an improvement that was significantly stronger than the control group.
Previous studies showed that the intrahepatic circulation in cirrhosis is not able to adapt to sudden increases in blood flow, such as that occurring after a meal, due to endothelial dysfunction. This leads to a brisk increase in portal pressure (estimated by the HVPG). This method is therefore useful to assess the efficacy of compounds potentially ameliorating intrahepatic endothelial dysfunction. Dark chocolate, which contains a high proportion of cocoa flavonoids such as cathechin and epicatechin- powerful antioxidants, increases NO availability in the systemic circulation and improves systemic endothelial function. We hypothesised that the antioxidant properties of dark chocolate could be beneficial in patients with cirrhosis, since they might improve intrahepatic endothelial dysfunction. Consequently, the aim of this study was to evaluate whether a dark chocolate-containing test meal may attenuate the post-prandial increase in HVPG in patients with cirrhosis and portal hypertension.

HVPG was measured at baseline and 30 minutes after the administration of a test meal supplemented by either dark or white chocolate. Portal vein blood flow and hepatic artery blood flow were measured by Doppler ultrasound. Catechins and NOx were determined for both timepoints.
FIELD: medicine, phytotherapy. SUBSTANCE: invention relates to the development of agents of natural origin for prophylaxis of diseases associated with disturbances of metabolism and enhancement of attenuated immunity. Invention proposes an agent eliciting adaptogenic activity comprising sea-buckthorn oil, amaranthus oil, flax oil and cedar oil taken in the following ratio of components, wt.-%: sea-buckthorn oil, 10-20; amaranthus oil, 40-70; flax oil, 10-20, and cedar oil, 10-20. Agent provides the improvement of state and recovers patients with different diseases due to enhancement of human body immune protective system. EFFECT: enhanced effectiveness of agent, valuable medicinal properties of agent. 4 tbl
PURPOSE:To obtain a vascular hyperplasia suppressor and a smooth muscle cell migration suppressor each containing a 7-thiaprostaglandin E1 compound as an active ingredient. CONSTITUTION:These agents contain each a compound of the formula (R<1> is H, an alkyl or a cation: R<2> is H or methl; R<3> is an alkyl or a cycloalkyl; (n) is 0 or 1; * is an asymmetric C). e.g. (17R)-17,20-dimethyl-7-thiaprostaglandin E1 methyl ester as an active ingredient. This compound is useful as a suppressor for vascular hyperplasia or obstruction mainly caused by migration or proliferation of a vascular smooth muscle cell after various angioplasties such as percutaneous coronary artery plastic operation, artery bypass ans grafting of organs. The administratoin of the compound is preferably per oral or intravenous and the daily does of the 7-thaipristaglandin E1 compound is 1 mug-1 mg/adult.
BACKGROUND: Radical radiotherapy for muscle-invasive bladder cancer (MIBC) is challenging due to large variations in bladder shape, size and volume during treatment, with drinking protocols often employed to mitigate geometric uncertainties. Utilising adaptive radiotherapy together with CBCT imaging to select a treatment plan that best fits the bladder target and reduce normal tissue irradiation is an attractive option to compensate for anatomical changes. The aim of this retrospective study was to compare a bladder empty (BE) protocol to a bladder filling (BF) protocol with regards to variations in target volumes, plan of the day (PoD) selection and plan dosimetry throughout treatment.
METHODS: Forty patients were included in the study; twenty were treated with a BE protocol and twenty with a BF protocol to a total prescribed dose of 55 Gy in 20 fractions. Small, medium and large bladder plans were generated using three different CTV to PTV margins. Bladder (CTV) volumes were delineated on planning CTs and online pre-treatment CBCTs. Differences in CTV volumes throughout treatment, plan selection, PTV volumes and resulting dose metrics were compared for both protocols.
RESULTS: Mean bladder volume differed significantly on both the planning CTs and online pre-treatment CBCTs between the protocols (p < 0.05). Significant differences in bladder volumes were observed between the planning CT and pre-treatment CBCTs for BF (p < 0.05) but not for BE (p = 0.11). Both protocols saw a significant decrease in bladder volume between first and final treatment fractions (p < 0.05). Medium plans were preferentially selected for BE whilst when using the BF protocol the small plan was chosen most frequently. With no significant change to PTV coverage between the protocols, the volume of body receiving 25.0-45.8 Gy was found to be significantly smaller for BE patients (p < 0.05).
CONCLUSIONS: This work provides evidence in favour of a BE protocol compared to a BF protocol for radical radiotherapy for MIBC. The smaller treatment volumes observed in the BE protocol led to reduced OAR and total body doses and were also observed to be more consistent throughout the treatment course. These results highlight improvements in dosimetry for patients who undergo a BE protocol for MIBC.
<P>PROBLEM TO BE SOLVED: To provide a method which does not act on microorganisms on a healthy skin, effectively controls proliferation of microorganisms on a skin part having reduced barrier functions, is not germicidal, does not concentrate resistant microorganisms and makes the skin healthy and to obtain an external preparation for skin used therefor.  <P>SOLUTION: The external preparation for skin comprises a protein that is derived from a bacterium selected from bacteria belonging the genus Lactobacillus, Bifidobacterium, Escherichia, Salmonella, Aeromonas, Streptococcus, Staphylococcus, Helicobacter, Campylobacter and Yersinia and has adhesivity to an extracellular matrix. The method for preventing adhesion of microorganisms harmful to the skin comprises using the external preparation for skin. The method for preventing proliferation of microorganisms harmful to skin comprises using the external preparation for skin. The method for producing the external preparation for skin comprising a protein having adhesivity to the extracellular matrix is provided.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
BACKGROUND: Up to 30% of people infected with SARS-CoV-2 report disabling symptoms 2 years after the infection. Over 100 persistent symptoms have been associated with Post-Acute COVID-19 Symptoms (PACS) and/or long-COVID, showing a significant clinical heterogeneity. To develop effective, patient-targeted treatment, a better understanding of underlying mechanisms is needed. Epigenetics has helped elucidating the pathophysiology of several health conditions and it might help unravelling inter-individual differences in patients with PACS and long-COVID. As accumulating research is exploring epigenetic mechanisms in PACS and long-COVID, we systematically summarized the available literature on the topic.
METHODS: We interrogated five databases (Medline, Embase, Web of Science, Scopus and medXriv/bioXriv) and followed PRISMA and SWiM guidelines to report our results.
RESULTS: Eight studies were included in our review. Six studies explored DNA methylation in PACS and/or long-COVID, while two studies explored miRNA expression in long-COVID associated with lung complications. Sample sizes were mostly small and study quality was low or fair. The main limitation of the included studies was a poor characterization of the patient population that made a homogeneous synthesis of the literature challenging. However, studies on DNA methylation showed that mechanisms related to the immune and the autonomic nervous system, and cell metabolism might be implicated in the pathophysiology of PACS and long-COVID.
CONCLUSION: Epigenetic changes might help elucidating PACS and long-COVID underlying mechanisms, aid subgrouping, and point towards tailored treatments. Preliminary evidence is promising but scarce. Biological and epigenetic research on long-COVID will benefit millions of people suffering from long-COVID and has the potential to be transferable and benefit other conditions as well, such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). We urge future research to employ longitudinal designs and provide a better characterization of included patients.
A medical procedure schedule is generated by retrieving a plurality of images at a complexity analysis module. Each image is associated with a corresponding medical procedure, and the medical procedures are to be scheduled. Each image is processed at the complexity analysis module to extract a value for a corresponding complexity metric. A characterization for each medical procedure is generated based at least partially on the complexity metric. A time estimation for each medical procedure is generated based on the characterization. A set of resources available for performing the plurality of medical procedures is determined, including operating rooms and medical teams. At least one operating room and medical team is allocated to each medical procedure, and a schedule is generated based on the time estimation associated with each medical procedure and the allocated operating room and medical team.
Children in the intervention group will immediately receive intravenous 5ml/kg 10% dextrose, Dextrose administration will continue as a maintenance infusion of intravenous 10% dextrose for 24 hours at standard maintenance rates. Capillary blood glucose monitoring will be repeated at 30 minute intervals with repeated equivalent bolus doses given until levels reach ≥5.0mmol/l. All children will be kept in the emergency department for a minimum of 60 minutes and have their vital signs checked at discharge from the emergency room to the ward.
The study will be conducted in three phases. Subjects who have been treated commercially with TAVR with a SAPIEN 3 valve and are being discharged to home will be eligible for Phase 1. Once consented prior to discharge, patients will complete the KCCQ, PROMIS Questionnaires, 5m walk, chair stand, and handgrip tests. During phase 1, all subjects will have a Fitbit and answer quality of life questions on the iPad about their activities and quality of life. After 30 days, the subject will return to complete the PROMIS Questionnaires, 5m walk, chair stand, balance tests, and handgrip tests, as well as a KCCQ. If the subject has consistently provided data throughout Phase 1, they will be asked to continue on to Phases 2 and 3 and complete a 6 minute walk test at this baseline visit. For Phase 2, subjects will be randomized to one of two arms. In one arm, they will have a daily activity goal and resistance exercises; in the other arm, there will not be a daily activity goal and no resistance exercises given. After 6 weeks, the subject will return to complete the 5m walk, 6 minute walk test, chair stand, balance tests, and handgrip tests, PROMIS Questionnaires, as well as a KCCQ. Five months after enrollment into Phase 2, subjects will be given a Fitbit to track their daily activity for 1 week (Phase 3). They will also complete a KCCQ, PROMIS Questionnaires, and end of study questionnaire.
Disclosed in the invention are a glutathione yeast, a preparation method and a use of the product. The production method comprises the following steps: after multi-stage seed cultivation of a glutathione yeast strain, the glutathione yeast strain being transferred to a fermentation tank to perform cultivation, and fermenting to obtain a yeast rich in glutathione. In the cultivation process, the duration control is performed in three stages, comprising a thallus growth stage, a glutathione initial synthesis stage, and a glutathione accelerated synthesis stage. The respiratory quotient value in the thallus growth stage is 1.0-1.2; the respiratory quotient value of the glutathione initial synthesis stage is 0.7-1.0; and the respiratory quotient value of the glutathione accelerated synthesis stage is 0.5-0.7. In the method, the content of glutathione in yeast cells can be increased to 12-20%, which is a relatively high level. Furthermore, glutathione nutritional yeast, glutathione yeast extract, and glutathione yeast hydrolysate products with specific contents can be developed by means of quantitatively extracting the yeast intracellular glutathione, and co-production of various glutathione products can be realized.
BACKGROUND: Management of facial fractures is variable. Understanding how time to operative management impacts outcomes can help standardize practice.
METHODS: Retrospective analysis of the ACS Trauma Quality Improvement Program (TQIP) database between 2016 and 2019. Adult patients with operative facial fractures were isolated by ICD-10 procedure codes, and further stratified by fracture location, including the mandible, orbit, maxilla, zygoma, and frontal bone. Multivariable logistic regression was conducted to predict in-hospital complications (both surgical and systemic complications) adjusting for time-to-operation, comorbidities, fracture location, AIS, and demographics.
RESULTS: 1678 patients with operative facial fractures were identified. The median time-to-operation was 2 days (IQR 1.0-2.0 days). Most patients only had one operative fracture (95 %) and orbital fracture was the most common (44 %). The overall complication rate was higher for those operated after 2 days compared to those operated between 1 and 2 days and within 24 h (2.8 % vs 0.6 % vs 0.7 %; p < 0.001). Patients who were operated on after 48 h exhibited an increased risk of any complication (OR 4.72, 95 % CI 1.49-16.6, p = 0.010) on multivariable models.
CONCLUSION: Delays in the management of facial fractures are associated with more in-hospital complications. However, the incidence of short-term postoperative complications remains low. Injury characteristics are the primary predictor of delays in operation, however Hispanic patients independently experienced delays in care.
BACKGROUND: Hair loss is a widespread health problem that affects numerous individuals and is associated with age, lack of sleep, stress, endocrine problems, and other problems. Caffeine exerts various pharmacological effects, particularly after ingestion. The caffeine-induced inhibition of phosphodiesterases can increase intracellular cAMP concentrations, ultimately resulting in stimulatory effects on cell metabolism and proliferation. Hence, caffeine has been confirmed to inhibit hair loss caused by premature termination of the hair growth phase. Adenosine also improves hair loss by stimulating hair growth and thickening hair shafts. However, further empirical evidence is required to comprehensively assess the efficacy of hair loss treatment and prevention using a formulation of caffeine and adenosine in specific proportions in shampoos.
OBJECTIVES: This study aimed to evaluate a shampoo with caffeine and adenosine as a daily scalp care product for hair loss in 77 subjects aged 18-60 years.
METHODS: The overall and local hair densities were assessed using professional cameras and dermoscopes at different magnifications and distances. Five hairs that came off the participant's head were randomly selected to measure hair diameter. The self-assessment questionnaires were filled on third month of product use.
RESULTS: The combination of caffeine and adenosine in the shampoo significantly enhanced hair density compared to that of the baseline. The results revealed a significant reduction in hair loss. The hair diameters of the subjects did not change significantly. Most of the participants (71.05%) were satisfied with their hair after using the product.
CONCLUSIONS: Shampoos containing caffeine and adenosine have been demonstrated to exert therapeutic benefits for reducing hair loss.
Ultrasound guidance is particularly useful for percutaneous injections in the diagnosis and management of painful conditions of the ankle and foot. The injectates used include steroids and local anesthetics, such as lidocaine, mepivacaine, bupivacaine, ropivacaine, and platelet-rich plasma. Osteoarthritis is the main indication for joint injections. Joints amenable to being injected include the tibiotalar, subtalar, midtarsal, and metatarsophalangeal joints. Tendon injections mainly involve the Achilles, peroneus, extensors, and tibialis tendons, while plantar fascia injections are useful for treating plantar fasciitis and plantar fibromatosis. Forefoot injections include joint arthritis, intermetatarsal bursitis, and Morton neuroma. The standardized approaches and doses reviewed in this paper are based on the authors' experience and can lead to high success in symptomatic relief for various conditions. These injections can be curative or serve as a guide to identify the source of pain when surgery or other therapeutic options are planned.
Part B: Dose escalation of SG301 SC will be done in Systemic lupus erythematosus subjects in 4 dose groups, namely 2 mg/kg, 4 mg/kg, 8 mg/kg, and 12 mg/kg dose groups. 2 subjects will be randomized to SG301 SC injection in an 8:2 ratio at each dose group.
This group will participate in the weekly "Healthy Creations" classes for 8 weeks presented by a Registered Dietitian and a certified fitness trainer. This is a community based lifestyle intervention program.
A preparation method of Nostoc commune ethanoic extract capable of inhibiting fat accumulation and reducing body fat includes: drying and grinding fresh Nostoc commune to be Nostoc commune powder, and using 95% ethanol to extract the Nostoc commune powder so as to obtain the Nostoc commune ethanoic extract. The Nostoc commune ethanoic extract with the concentration of 1~50<mu>g /mL is used to be a raw material of Nostoc commune healthy food, or a feed additive or a food product, so as to inhibit adipocyte proliferation and lipid accumulation. In addition, the Nostoc commune ethanoic extract can be further extracted to purify the raw materials of Nostoc commune polysaccharides and triterpenes. Thereby, by the Nostoc commune ethanoic extract having different antioxidant abilities and containing phytochemicals of being beneficial to human body, the effect of lowering pre-adipocyte proliferation and body fat can be observered in the 3T3-L1 cell culturing mode. Moreover, the noodle with 2% Nostoc commune has good consumer acceptance. After colding and dressing with sauce or performing a boiled cooking, the Nostoc commune in the noodle can not only inhibit triglycerides accumulation in adipocytes, but also reduce 3T3-L1 preadipocyte proliferation so as to achieve the effect of reducing adipocyte formation.
FuDan-GP2 subtype is Cold tumor type. Treatment regimen：anlotinib 12 mg PO, QD, 14 days on - 7 days off combined with everolimus 5 mg PO, QD.
Sleep symptoms, including excessive sleepiness, are frequently reported by patients with functional motor disorders (FMD). We aimed to classify the comorbid sleep disorders in FMD, and to investigate the relationship between subjective sleepiness and objective measures of hypersomnia, comparing them with data from people with central hypersomnia. A total of 37 patients (mean [SD] age 46.4 [11.2] years) with clinically definite FMD, and 17 patients (mean [SD] age 41.1 [11.6] years) with central hypersomnia underwent structured medical and sleep history, neurological examination, polysomnography, multiple sleep latency test (MSLT), and questionnaires assessing sleepiness, fatigue, and depression. In all, 23 patients with FMD (62%) reported excessive daytime sleepiness. Evidence of specific sleep disorders was identified in our cohort, with 35% having restless legs syndrome; 49% obstructive sleep apnea; and 8% periodic limb movements in sleep; however, the presence of these disorders was not correlated with subjective sleepiness. Patients with FMD with self-reported sleepiness reported higher fatigue (p = 0.002), depression (p = 0.002), and had longer sleep latencies in the MSLT (p < 0.001) compared to the patients with central hypersomnia. No correlation was found between subjective and objective sleepiness in either group. Fatigue positively correlated with self-reported sleepiness in patients with FMD (p < 0.001). This study did not find objective correlates of increased sleepiness in patients with FMD. While sleep abnormalities were found to be common in FMD, they were not correlated with self-reports of excessive sleepiness. Positive correlations between self-reported sleepiness and fatigue support the current unified model of non-motor symptoms in FMD.
Continuous subcutaneous insulin infusion (CSII) with Accu-Chek® Solo Micropump system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.